Karyopharm staffing up in MA; How often do biobucks come through?;

@FierceBiotech:  Gilead's 'open to suggestion' on its next big M&A splash. Articles | Follow @FierceBiotech

@JohnCFierce: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes to "meh" cancer drugs. | Follow @JohnCFierce

@DamianFierce: Shouts to the 19 $OPHT workers who won $58M on the New York lottery. Article | Follow @DamianFierce

> Karyopharm Therapeutics ($KPTI) is planning to hire about 50 people throughout the year as it presses forward with a stable of cancer candidates. Story

> Isis ($ISIS) pocketed another $10 million milestone payment in its wide-ranging collaboration with Biogen ($BIIB). More

> Atlas Venture's Bruce Booth takes a look at how often those backloaded biotech deals actually pay out their promised milestones. Post

Medical Device News

@FierceMedDev: Medtronic to test renal denervation as treatment for atrial fibrillation. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Kaiser backs startup in $12.5M round to speed healthcare data integration. News | Follow @VarunSaxena2

@EmilyWFierce: Abbott grabs #FDA OK for early pregnancy blood test. FierceDiagnostics Story | Follow @EmilyWFierce

> Greatbatch spins off neurostimulation unit to speed up growth. Article.

> Ninox gets $10M Series B to get wearable sleep apnea device through regulators. More

Pharma News

@FiercePharma: From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1. Story | Follow @FiercePharma

@EricPFierce: Drug shortages become way for #Mylan to parry against #Teva but will the FTC care? More | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday: Teva CEO 'takes the high road' to rebut Mylan chairman's attack. News | Follow @CarlyHFierce

> Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend. Article

> Novartis faces more kickback scrutiny after $45M Express Scripts settlement. Story